Literature DB >> 15236040

The hemodynamic and metabolic changes in prostaglandin E1-induced hypotension in dogs--a comparative study with trimetaphan-induced hypotension.

Y T Nam1, S Takahashi, M Tominaga, J Yoshitake.   

Abstract

The hemodynamic and metabolic changes in hypotensive state induced with prostaglandin E1 (PGE1) or trimetaphan (TMT) infusion were investigated in dogs. Mean arterial pressure was decreased by about 50% with 1.58 microg/kg/min of PGE1 or 45 microg/kg/min of TMT. Heart rate, pulmonary capillary wedge pressure and central venous pressure remained virtually unchanged in the two groups. Cardiac output was well maintained in PGE1 group, whereas cardiac output showed the tendency to decline in TMT group. Greater reduction in systemic vascular resistance was seen in PGE1 group than in TMT group. Pulmonary vascular resistance showed no significant change in PGE1 group, whereas it increased significantly in TMT group. Gradual decreases in arterial pH, PaO2 and base excess and slight but significant increase in PaCO2 was observed in PGE1 group, and these abnormalities recovered 30 min after hypotension. Abnormalities in blood gases and acid-base balance were considerably more severe and prolonged in TMT group compared with those in PGE1 group. Blood lactate and pyruvate concentrations showed no significant changes in PGE1 group, whereas substantial elevation was seen in L/P ratio especially 30 min after induction of hypotension in TMT group. Oxygen consumption showed minimal changes in PGE1 group, whereas a significant decrease was observed in TMT group. The conclusions derived from these results are as follows; 1) PGE1 maintained cardiac output better than TMT, probably because of its direct inotropic action on the heart, and of its greater reduction of systemic vascular resistance than TMT. 2) PGE1 seemed to provide the better blood perfusion throughout the body than TMT. 3) PGE1 showed less possibility to produce the metabolic derangement compared with TMT.

Entities:  

Year:  1989        PMID: 15236040     DOI: 10.1007/s0054090030210

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  15 in total

1.  Properties of human seminal plasma.

Authors:  M W Goldblatt
Journal:  J Physiol       Date:  1935-05-13       Impact factor: 5.182

2.  On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin).

Authors:  U S von Euler
Journal:  J Physiol       Date:  1936-11-06       Impact factor: 5.182

3.  Prostaglandins as modulators of the autonomic nervous system.

Authors:  M J Brody; P J Kadowitz
Journal:  Fed Proc       Date:  1974-01

4.  Blockade of adrenergic vasoconstrictor responses in the dog by prostaglandins E 1 and A 1 .

Authors:  P J Kadowitz; C S Sweet; M J Brody
Journal:  J Pharmacol Exp Ther       Date:  1971-12       Impact factor: 4.030

5.  The redox state of nicotinamide adenine dinucleotide in the cytoplasm and mitochondria of rat liver.

Authors:  H A Krebs
Journal:  Adv Enzyme Regul       Date:  1967

6.  Influence of prostaglandin E1 on the terminal vascular bed.

Authors:  R Weiner; G Kaley
Journal:  Am J Physiol       Date:  1969-08

7.  Prostaglandin E 1 and cardiac arrhythmia.

Authors:  W G Zijlstra; J R Brunsting; F ten Hoor; A J Vergroesen
Journal:  Eur J Pharmacol       Date:  1972-05       Impact factor: 4.432

8.  Cardiovascular effects of prostaglandin E1.

Authors:  J Nakano; J R McCurdy
Journal:  J Pharmacol Exp Ther       Date:  1967-06       Impact factor: 4.030

9.  Epinephrine-induced arrhythmias: effect of exogenous prostaglandins and prostaglandin synthesis inhibition during halothane-O2 anesthesia in the dog.

Authors:  N L Pace; A Ohmura; K C Wong
Journal:  Anesth Analg       Date:  1979 Sep-Oct       Impact factor: 5.108

10.  Prostaglandin E1 as a hypotensive drug during general anaesthesia.

Authors:  F Goto; E Otani; S Kato; T Fujita
Journal:  Anaesthesia       Date:  1982-05       Impact factor: 6.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.